FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

33766211000001100: Zicron PR 30mg tablets (Bristol Laboratories Ltd) (product)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 01-Feb 2017. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
102652001000001113 Zicron PR 30mg tablets (Bristol Laboratories Ltd) (product) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
102652101000001114 Zicron PR 30mg tablets (Bristol Laboratories Ltd) en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Has excipient Excipient not declared true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Has NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction indicator NHS dm+d (dictionary of medicines and devices) AMP (actual medicinal product) availability restriction none true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Is a Gliclazide 30mg modified-release tablets true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Has NHS dm+d (dictionary of medicines and devices) controlled drug category Controlled drug category No Controlled Drug Status true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Is a Gliclazide 30mg m/r tablet false Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Has active ingredient Gliclazide true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Has manufactured dose form Modified-release oral tablet true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) VMP prescribing status (attribute) VMP valid as a prescribable product true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) VMP non-availability indicator Available true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Has specific active ingredient Gliclazide true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Has dispensed dose form Modified-release oral tablet true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Has excipient Lactose false Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Is a Zicron PR true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Is a Actual medicinal product true Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) Is a Gliclazide 30mg modified-release tablets false Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Zicron PR 30mg tablets (Bristol Laboratories Ltd) 28 tablet 2 x 14 tablets Has AMP True Zicron PR 30mg tablets (Bristol Laboratories Ltd) Inferred relationship Existential restriction modifier
Zicron PR 30mg tablets (Bristol Laboratories Ltd) 56 tablet 4 x 14 tablets Has AMP True Zicron PR 30mg tablets (Bristol Laboratories Ltd) Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start